Zydus group has entered into an in-licensing agreement with Neovii, a Switzerland based global biopharmaceutical company to launch Grafalon, an immunosuppresant extensively used in solid organ transplants and stem cell transplant, in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine. With the inclusion of ?Grafalon, Zydus Trans-immune becomes a leading player in transplant-immuno therapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant.
Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation. However, one of the major challenges in organ transplantation is graft rejection. In most cases, transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Likewise, Stem Cell Transplantation remains key treatment option for those suffering from haematological conditions including malignancies. Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon..
Grafalon (formerly commercialized as ATG Fresenius) is used as a part of immunosuppressive regimens (induction protocol) for the prevention and treatment of rejection in solid organ transplantation, prevention of graft versus host disease in stem cell transplantation.
As an rATG anti-human T-lymphocyte globulin, Grafalon enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world. More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon. Currently an estimated 10,000 solid organ transplant & stem cell transplants are taking place annually across 200 plus transplant centres in India. Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression
